metastatic colorectal cancer
Oncology · 2010–2017
3decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Jul 2017 | Not recommended | unclear |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Nov 2016 | Not recommended | input received |
| cetuximab First-line treatment of patients with K-RAS wild type (K-RAS wt) metastatic colorectal cancer (mCRC). | Mar 2010 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.